Amarin (AMRN) Slips as FDA Updates Orange Book
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp Plc (NASDAQ: AMRN) shares slump in afternoon trading Friday following the FDA updating its Orange Book.
To access the Vascepa page at the FDA, click here.
Shares are down 0.7 percent today.
To access the Vascepa page at the FDA, click here.
Shares are down 0.7 percent today.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin presents REDUCE-IT legacy analysis at ESC Congress 2026
- MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug
- AstraZeneca's Tagrisso combo shows Phase III benefit in lung cancer
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
